Company intelligence / Profile preview

Sensible Biotechnologies

Oxford, England, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

The company has demonstrated the capability to produce pure, non-immunogenic, and highly functional mRNA using cell-based methods, overcoming conventional in vitro synthesis limitations such as immunogenic double-stranded RNA, cost, and scalability. It has letters of intent from 10 biotech companies and research groups wishing to test its mRNA; major co-development partnership with Ginkgo Bioworks.

Therapeutic areas: OncologyOtherInfectious DiseasesRare Diseases
Modalities: mRNA-based drugsBiologic
Industry: Non-Drug Biotech

Partnerships

Ginkgo Bioworks (platform co-development)Letters of intent from 10 biotech companies/research groups

Beyond the preview

Go deeper on Sensible Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensible Biotechnologies.

Explore the full profile